Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Ossium Health, Inc.
Essen Biotech
Roswell Park Cancer Institute
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
ARCE Therapeutics, Inc.
Children's Hospital Medical Center, Cincinnati
M.D. Anderson Cancer Center
Thomas Jefferson University
Dana-Farber Cancer Institute
Fred Hutchinson Cancer Center
Mayo Clinic
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
CERo Therapeutics Holdings, Inc.
City of Hope Medical Center
University of Illinois at Chicago
Case Comprehensive Cancer Center
AvenCell Therapeutics, Inc.
King Faisal Specialist Hospital & Research Center
Instituto Nacional de Cancer, Brazil
Vastra Gotaland Region
Melbourne Health
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
University of Birmingham
Celyad Oncology SA